Filipa C Lynce (Filipa Lynce)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 59

Top Venues

Current oncology reports

Nature communications

NPJ breast cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Georgetown University Medical Center

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Georgetown University Medical Center Jul 01 2018 - Jul 10 2020

United States

Associate Professor :: Oncology

Georgetown University Medical Center Jan 28 2015 - Jun 30 2018

United States

Assistant Professor :: Oncology

Publications

Filipa C Lynce, Nancy U Lin
From Serendipity to Intention: Development of Brain-Penetrant PARP1-Selective Inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (7) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Nolan Priedigkeit, Beth Harrison, Robert Shue, Melissa Hughes, Yvonne Li, Gregory J Kirkner, Liam F Spurr, Marie Claire Remolano, Sarah Strauss, Janet Files, Anne-Marie Feeney, Libby Grant, Ayesha Mohammed-Abreu, Ana Garrido-Castro, Romualdo Barroso Sousa, Brittany Bychkovsky, Faina Nakhlis, Jennifer R Bellon, Tari A King, Eric P Winer, Neal Lindeman, Bruce E Johnson, Lynette Sholl, Deborah Dillon, Beth Overmoyer, Sara M Tolaney, Andrew Cherniack, Nancy U Lin, Filipa C Lynce
Clinicogenomic characterization of inflammatory breast cancer. bioRxiv : the preprint server for biology (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Paolo Tarantino, Julieta Leone, Carlos T Vallejo, Rachel A Freedman, Adrienne G Waks, Olga Martínez-Sáez, Ana Christina Garrido-Castro, Filipa C Lynce, Nabihah Tayob, Nancy U Lin, Sara M Tolaney, José Pablo Leone
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A Mittendorf, Tari A King, Anna Weiss, Ann H Partridge, Brittany L Bychkovsky, Curigliano Giuseppe, Nabihah Tayob, Nancy U Lin, Judy E Garber, Sara M Tolaney, Filipa C Lynce
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer. NPJ breast cancer 10 (1) (2024)
Isabelle Bedrosian, Mark R Somerfield, Maria Isabel Achatz, Judy C Boughey, Curigliano Giuseppe, Sue Friedman, Wendy K Kohlmann, Allison W Kurian, Christine Laronga, Filipa C Lynce, Barbara S Norquist, Jennifer K Plichta, Patricia Rodriguez, Payal Deepak Shah, Marc Tischkowitz, Marie Wood, Siddhartha Yadav, Katherine Yao, Mark E Robson
Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (5) (2024)
Ko Un Park, Stuart Lipsitz, Laura S Dominici, Filipa C Lynce, Christina A Minami, Faina Nakhlis, Adrienne G Waks, Laura E Warren, Nadine Eidman, Jeannie Frazier, Lourdes Hernandez, Carla Leslie, Susan Rafte, Delia Stroud, Joel S Weissman, Tari A King, Elizabeth A Mittendorf
Generative artificial intelligence as a source of breast cancer information for patients: Proceed with caution. Cancer (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Mengmeng Zhang, Kaiwen Zhou, Zilin Wang, Ting Liu, Laura E Stevens, Filipa C Lynce, Wendy Y Chen, Sui Peng, Yubin Xie, Duanyang Zhai, Qianjun Chen, Yawei Shi, Huijuan Shi, Zhongyu Yuan, Xiaoping Li, Juan Xu, Zhenhai Cai, Jian-Ping Guo, Nan Shao, Ying Lin
A Subpopulation of Luminal Progenitors Secretes Pleiotrophin to Promote Angiogenesis and Metastasis in Inflammatory Breast Cancer. Cancer research 84 (11) (2024)
Mengmeng Zhang, Kaiwen Zhou, Zilin Wang, Ting Liu, Laura E Stevens, Filipa C Lynce, Wendy Y Chen, Sui Peng, Yubin Xie, Duanyang Zhai, Qianjun Chen, Yawei Shi, Huijuan Shi, Zhongyu Yuan, Xiaoping Li, Juan Xu, Zhenhai Cai, Jian-Ping Guo, Nan Shao, Ying Lin
A Subpopulation of Luminal Progenitors Secretes Pleiotrophin to Promote Angiogenesis and Metastasis in Inflammatory Breast Cancer. Cancer research 84 (11) (2024)
Ilana Schlam, Joshua Dower, Filipa C Lynce
Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next? Current oncology reports 26 (4) (2024)
Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A Mittendorf, Tari A King, Anna Weiss, Ann H Partridge, Brittany L Bychkovsky, Curigliano Giuseppe, Nabihah Tayob, Nancy U Lin, Judy E Garber, Sara M Tolaney, Filipa C Lynce
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer. NPJ breast cancer 10 (1) (2024)
Isabelle Bedrosian, Mark R Somerfield, Maria Isabel Achatz, Judy C Boughey, Curigliano Giuseppe, Sue Friedman, Wendy K Kohlmann, Allison W Kurian, Christine Laronga, Filipa C Lynce, Barbara S Norquist, Jennifer K Plichta, Patricia Rodriguez, Payal Deepak Shah, Marc Tischkowitz, Marie Wood, Siddhartha Yadav, Katherine Yao, Mark E Robson
Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (5) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Mengmeng Zhang, Kaiwen Zhou, Zilin Wang, Ting Liu, Laura E Stevens, Filipa C Lynce, Wendy Y Chen, Sui Peng, Yubin Xie, Duanyang Zhai, Qianjun Chen, Yawei Shi, Huijuan Shi, Zhongyu Yuan, Xiaoping Li, Juan Xu, Zhenhai Cai, Jian-Ping Guo, Nan Shao, Ying Lin
A Subpopulation of Luminal Progenitors Secretes Pleiotrophin to Promote Angiogenesis and Metastasis in Inflammatory Breast Cancer. Cancer research 84 (11) (2024)
Paolo Tarantino, Julieta Leone, Carlos T Vallejo, Rachel A Freedman, Adrienne G Waks, Olga Martínez-Sáez, Ana Christina Garrido-Castro, Filipa C Lynce, Nabihah Tayob, Nancy U Lin, Sara M Tolaney, José Pablo Leone
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A Mittendorf, Tari A King, Anna Weiss, Ann H Partridge, Brittany L Bychkovsky, Curigliano Giuseppe, Nabihah Tayob, Nancy U Lin, Judy E Garber, Sara M Tolaney, Filipa C Lynce
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer. NPJ breast cancer 10 (1) (2024)
Paolo Tarantino, Julieta Leone, Carlos T Vallejo, Rachel A Freedman, Adrienne G Waks, Olga Martínez-Sáez, Ana Christina Garrido-Castro, Filipa C Lynce, Nabihah Tayob, Nancy U Lin, Sara M Tolaney, José Pablo Leone
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Mengmeng Zhang, Kaiwen Zhou, Zilin Wang, Ting Liu, Laura E Stevens, Filipa C Lynce, Wendy Y Chen, Sui Peng, Yubin Xie, Duanyang Zhai, Qianjun Chen, Yawei Shi, Huijuan Shi, Zhongyu Yuan, Xiaoping Li, Juan Xu, Zhenhai Cai, Jian-Ping Guo, Nan Shao, Ying Lin
A subpopulation of luminal progenitors secretes pleiotrophin to promote angiogenesis and metastasis in inflammatory breast cancer. Cancer research (2024)
Ilana Schlam, Joshua Dower, Filipa C Lynce
Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next? Current oncology reports 26 (4) (2024)
Ilana Schlam, Joshua Dower, Filipa C Lynce
Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next? Current oncology reports 26 (4) (2024)
Filipa C Lynce, Nancy U Lin
From serendipity to intention: development of brain penetrant PARP1 selective inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Isabelle Bedrosian, Mark R Somerfield, Maria Isabel Achatz, Judy C Boughey, Curigliano Giuseppe, Sue Friedman, Wendy K Kohlmann, Allison W Kurian, Christine Laronga, Filipa C Lynce, Barbara S Norquist, Jennifer K Plichta, Patricia Rodriguez, Payal Deepak Shah, Marc Tischkowitz, Marie Wood, Siddhartha Yadav, Katherine Yao, Mark E Robson
Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Isabelle Bedrosian, Mark R Somerfield, Maria Isabel Achatz, Judy C Boughey, Curigliano Giuseppe, Sue Friedman, Wendy K Kohlmann, Allison W Kurian, Christine Laronga, Filipa C Lynce, Barbara S Norquist, Jennifer K Plichta, Patricia Rodriguez, Payal Deepak Shah, Marc Tischkowitz, Marie Wood, Siddhartha Yadav, Katherine Yao, Mark E Robson
Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (5) (2024)
Ilana Schlam, Joshua Dower, Filipa C Lynce
Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next? Current oncology reports (2024)
Ilana Schlam, Joshua Dower, Filipa C Lynce
Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next? Current oncology reports 26 (4) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Kimia Sorouri, Filipa C Lynce, Colleen M Feltmate, Michelle R Davis, Michael G Muto, Panagiotis A Konstantinopoulos, Elizabeth H Stover, Allison W Kurian, Sarah J Hill, Ann H Partridge, Sara M Tolaney, Judy E Garber, Brittany L Bychkovsky
Endometrial Cancer Risk Among Germline BRCA1 / 2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps. JCO precision oncology 7 (2023)
Stefania Morganti, Brittany L Bychkovsky, Philip D Poorvu, Ana C Garrido-Castro, Anna Weiss, Caroline C Block, Ann H Partridge, Giuseppe Curigliano, Nadine M Tung, Nancy U Lin, Judy E Garber, Sara M Tolaney, Filipa C Lynce
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies. The oncologist (2023)
Kimia Sorouri, Filipa C Lynce, Colleen M Feltmate, Michelle R Davis, Michael G Muto, Panagiotis A Konstantinopoulos, Elizabeth H Stover, Allison W Kurian, Sarah J Hill, Ann H Partridge, Sara M Tolaney, Judy E Garber, Brittany L Bychkovsky
Endometrial Cancer Risk Among Germline BRCA1 / 2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps. JCO precision oncology 7 (2023)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. medRxiv : the preprint server for health sciences (2023)
Alexandra B Newman, Filipa C Lynce
Tailoring Treatment for Patients with Inflammatory Breast Cancer. Current treatment options in oncology (2023)
Ana Christina Garrido-Castro, Meredith M Regan, Samuel M Niman, Faina Nakhlis, Claire Remolano, Jennifer M Rosenbluth, Caroline Block, Laura E G Warren, Jennifer R Bellon, Eren Yeh, Beth T Harrison, Elizabeth Troll, Nancy U Lin, Sara M Tolaney, Beth A Overmoyer, Filipa C Lynce
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer. NPJ breast cancer 9 (1) (2023)
Kimia Sorouri, Filipa C Lynce, Colleen M Feltmate, Michelle R Davis, Michael G Muto, Panagiotis A Konstantinopoulos, Elizabeth H Stover, Allison W Kurian, Sarah J Hill, Ann H Partridge, Sara M Tolaney, Judy E Garber, Brittany L Bychkovsky
Endometrial Cancer Risk Among Germline BRCA1 / 2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps. JCO precision oncology 7 (2023)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. medRxiv : the preprint server for health sciences (2023)
Ilana Schlam, Raquel A Nunes, Filipa C Lynce
Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer. OncoTargets and therapy 15 (2022)
Laura E G Warren, Samuel M Niman, Marie C Remolano, Jean M Landry, Faina Nakhlis, Jennifer R Bellon, Ayal A Aizer, Nancy U Lin, Sara M Tolaney, Meredith M Regan, Beth A Overmoyer, Filipa C Lynce
Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer. Cancer 128 (23) (2022)
Paula R Pohlmann, Deena Graham, Tianmin Wu, Yvonne Ottaviano, Mahsa Mohebtash, Shweta Kurian, Donna McNamara, Filipa C Lynce, Robert Warren, Asma Dilawari, Suman Rao, Candace Mainor, Nicole Swanson, Ming T Tan, Claudine Isaacs, Sandra M Swain
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. Breast cancer research and treatment 196 (3) (2022)
Ilana Schlam, Paolo Tarantino, Stefania Morganti, Filipa C Lynce, Dario Trapani, Erica L Mayer, Ana Christina Garrido-Castro, Ada Waks, Sara M Tolaney
Emerging Targeted Therapies for Early Breast Cancer. Drugs 82 (14) (2022)
Filipa C Lynce, James T Williams, Meredith M Regan, Craig A Bunnell, Rachel A Freedman, Sara M Tolaney, Wendy Y Chen, Erica L Mayer, Ann H Partridge, Eric P Winer, Beth Overmoyer
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. Cancer chemotherapy and pharmacology 87 (5) (2021)
Bryan Paul Schneider, Guanglong Jiang, Tarah Jean Ballinger, Fei Shen, Christopher Chitambar, Rita Nanda, Carla Falkson, Filipa C Lynce, Christopher M Gallagher, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Karen Daily, Reshma L Mahtani, Michael A Thompson, Robert Graham, Maureen E Cooper, Dean C Pavlick, Lee A Albacker, Jeffrey Gregg, Jeffrey P Solzak, Yu-Hsiang Chen, Casey L Bales, Erica L Cantor, Bradley A Hancock, Nawal Kassem, Paul Helft, Bert O'Neil, Anna Maria V Storniolo, Sunil S Badve, Kathy D Miller, Milan Radovich
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (4) (2021)
Filipa C Lynce, Raquel Nunes
Role of Platinums in Triple-Negative Breast Cancer. Current oncology reports 23 (5) (2021)
Filipa C Lynce, Matthew J Blackburn, Rebecca Zhuo, Christopher Gallagher, Olwen M Hahn, Maysa Abu-Khalaf, Mahsa Mohebtash, Tianmin Wu, Paula R Pohlmann, Asma Dilawari, Shruti R Tiwari, Ami Chitalia, Robert Warren, Ming Tan, Ayesha N Shajahan-Haq, Claudine Isaacs
Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. Cancer 127 (19) (2021)
Filipa C Lynce, Ilana Schlam, Xue Geng, Beth N Peshkin, Sue Friedman, Julie Dutil, Zeina Nahleh, Claudia Campos, Charité Ricker, Patricia Rodriguez, Neelima Denduluri, Jaeil Ahn, Claudine Isaacs, Kristi D Graves
BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study. Journal of genetic counseling 30 (2) (2020)
Filipa C Lynce, Hongkun Wang, Emanuel F Petricoin, Paula R Pohlmann, Brandon Smaglo, Jimmy Hwang, Aiwu R He, Deepa S Subramaniam, John Deeken, John Marshall, Michael J Pishvaian
A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies. Cancer chemotherapy and pharmacology 84 (5) (2019)
Filipa C Lynce, Matthew J Blackburn, Ling Cai, Heping Wang, Larry Rubinstein, Pamela Harris, Claudine Isaacs, Paula R Pohlmann
Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials. Breast cancer research and treatment 168 (1) (2017)

Filipa C Lynce.css-eqlu8i{font-size:small;padding-left:4px;} (Filipa Lynce)

Publication Activity (10 Years)

Top Topics

Top Venues

Filipa C Lynce (Filipa Lynce)